EGFR and cancer: The insulin/IGF system also contributes to CRC resistance to both conventional and targeted anti-cancer agents, leading to increased PI3K/Akt signaling that hinders the apoptotic signals triggered by chemotherapeutic drugs and desensitizes CRC cells to the effect of anti-EGFR antibodies.